Колоректальный рак на фоне язвенного колита (обзор литературы)
https://doi.org/10.33878/2073-7556-2023-22-1-138-146
Аннотация
Язвенный колит (ЯК) — воспалительное заболевание кишечника, поражающее в основном людей молодого возраста. Одним из осложнений ЯК является развитие колоректального рака (КРР). В данном обзоре лите- ратуры рассмотрены эпидемиология, факторы риска развития, диагностика и скрининг, а также лекар- ственная профилактика КРР на фоне ЯК. Кроме того, описана тактика при дисплазии на фоне ЯК и раз- личные варианты хирургического лечения при развитии КРР. Учитывая недостаточность литературных данных для окончательного суждения о подходах к лечению рака толстой кишки (особенно прямой кишки) на фоне ЯК, достаточно актуальным представляется проведение дальнейших исследований по оценке как онкологических, так и функциональных результатов лечения, что может помочь в решении этой важной проблемы.
Об авторах
А. О. Расулов
Клинический госпиталь «Лапино» группы компаний «Мать и дитя»
1-е Успенское ш., д. 111, дер. Лапино, Московская обл.,143081
А. Э. Куликов
Клинический госпиталь «Лапино» группы компаний «Мать и дитя»
Россия
Россия
Куликов Артур Эдуардович
1-е Успенское ш., д. 111, дер. Лапино, Московская обл.,143081
Ж. М. Мадьяров
Клинический госпиталь «Лапино» группы компаний «Мать и дитя»
1-е Успенское ш., д. 111, дер. Лапино, Московская обл.,143081
З. Р. Расулов
Клинический госпиталь «Лапино» группы компаний «Мать и дитя»
1-е Успенское ш., д. 111, дер. Лапино, Московская обл.,143081
Список литературы
1. Sung H, Ferlay J, Siegel RL et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209–49. doi: 10.3322/CAAC.21660
2. Ивашкин В.Т., Шелыгин Ю.А., Халиф И.Л., и соавт. Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России по диагностике и лечению язвенного колита. Колопроктология. 2017:6–30. doi: 10.33878/2073-7556-2017-0-1
3. Kaplan GG, Ng SC. Understanding and Preventing the Global Increase of Inflammatory Bowel Disease. Gastroenterology. 2017;152:313–321.e2. doi: 10.1053/J.GASTRO.2016.10.020
4. Jess T, Simonsen J, Jorgensen KT, Pedersen BV, Nielsen NM, Frisch M. Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology. 2012;143:375–381. e1. doi: 10.1053/J.GASTRO.2012.04.016
5. Triantafillidis JK, Nasioulas G, Kosmidis PA. Colorectal Cancer and Inflammatory Bowel Disease: Epidemiology, Risk Factors, Mechanisms of Carcinogenesis and Prevention Strategies. Anticancer Research. Anticancer Res. 2009;29:2727–38.
6. Kulaylat MN, Dayton MT. Ulcerative colitis and cancer. J Surg Oncol. 2010;101:706–12. doi: 10.1002/JSO.21505
7. Ananthakrishnan AN, Cagan A, Cai T, Gainer VS, et al. Colonoscopy is Associated with a Reduced Risk for Colon Cancer and Mortality in Patients with Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2015;13:322. doi: 10.1016/J.CGH.2014.07.018
8. Sensi B, Bagaglini G, Bellato V, Cerbo D, et al. Management of Low Rectal Cancer Complicating Ulcerative Colitis: Proposal of a Treatment Algorithm. Cancers (Basel). 2021;13. doi: 10.3390/CANCERS13102350
9. Delaunoit T, Limburg PJ, Goldberg RM, Lymp JF, et al. Colorectal cancer prognosis among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006;4:335–42. doi: 10.1016/J.CGH.2005.12.035
10. Rutter MD, Saunders BP, Wilkinson KH, Rumbles S, et al. Thirtyyear analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology. 2006;130:1030–8. doi: 10.1053/J.GASTRO.2005.12.035
11. Dulai PS, Sandborn WJ, Gupta S. Colorectal cancer and dysplasia in inflammatory bowel disease: a review of disease epidemiology, pathophysiology, and management. Cancer Prev Res (Phila). 2016;9:887. doi: 10.1158/1940-6207.CAPR-16-0124
12. Nebbia M, Yassin NA, Spinelli A. Colorectal Cancer in Inflammatory Bowel Disease. Clin Colon Rectal Surg. 2020;33:305–17. doi: 10.1055/S-0040-1713748
13. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:526. doi: 10.1136/GUT.48.4.526
14. Söderlund S, Brandt L, Lapidus A, Karlén P, et al. Decreasing time-trends of colorectal cancer in a large cohort of patients with inflammatory bowel disease. Gastroenterology. 2009;136:1561–7. doi: 10.1053/J.GASTRO.2009.01.064
15. Dyson JK, Rutter MD. Colorectal cancer in inflammatory bowel disease: What is the real magnitude of the risk? World J Gastroenterol. 2012;18:3839. doi: 10.3748/WJG.V18.I29.3839
16. Itzkowitz SH, Present DH, Binder V, Boland CR, et al. Consensus conference: Colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:314–21. doi: 10.1097/01.MIB.0000160811.76729.D5
17. Reznicek E, Arfeen M, Shen B, Ghouri Y. Colorectal Dysplasia and Cancer Surveillance in Ulcerative Colitis. Dis (Basel, Switzerland). 2021;9:86. doi: 10.3390/DISEASES9040086
18. Collins PD. Strategies for detecting colon cancer and dysplasia in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:860–3. doi: 10.1097/MIB.0B013E3182802C6A
19. Collins PD, Mpofu C, Watson AJ, Rhodes JM. Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. Cochrane Database Syst Rev. 2006. doi: 10.1002/14651858.CD000279.PUB3
20. Lutgens M, Oldenburg B, Siersema PD, Van Bodegraven AA, et al. Colonoscopic surveillance improves survival after colorectal cancer diagnosis in inflammatory bowel disease. Br J Cancer. 2009;101:1671. doi: 10.1038/SJ.BJC.6605359
21. Adamina M, Angriman I, Bemelman WA, Biancone L, et al. European evidence based consensus on surgery for ulcerative colitis. J Crohns Colitis. 2015;9:4–25. doi: 10.1016/J.CROHNS.2014.08.012
22. Kim ER, Chang DK. Colorectal cancer in inflammatory bowel disease: The risk, pathogenesis, prevention and diagnosis. World J Gastroenterol. 2014;20:9872. doi: 10.3748/WJG.V20.I29.9872
23. Pulusu SSR, Lawrance IC. Dysplasia and colorectal cancer surveillance in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2017;11:711–22. doi: 10.1080/17474124.2017.1327347
24. Kiesslich R, Fritsch J, Holtmann M, Koehler HH, et al. Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology. 2003;124:880–8. doi: 10.1053/GAST.2003.50146
25. Lakatos PL, Lakatos L. Risk for colorectal cancer in ulcerative colitis: Changes, causes and management strategies. World J Gastroenterol. 2008;14:3937. doi: 10.3748/WJG.14.3937
26. Riddell RH, Goldman H, Ransohoff DF, Appelman HD, et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol. 1983;14:931–68. doi: 10.1016/S0046-8177(83)80175-0
27. Navaneethan U, Jegadeesan R, Gutierrez NG, Venkatesh PGK, et al. Progression of low-grade dysplasia to advanced neoplasia based on the location and morphology of dysplasia in ulcerative colitis patients with extensive colitis under colonoscopic surveillance. J Crohns Colitis. 2013;7. doi: 10.1016/J.CROHNS.2013.06.006
28. Heuschen UA, Hinz U, Allemeyer EH, Stern J, et al. Backwash ileitis is strongly associated with colorectal carcinoma in ulcerative colitis. Gastroenterology. 2001;120:841–7. doi: 10.1053/GAST.2001.22434
29. Hurlstone DP, Sanders DS, Atkinson R, Hunter MD, et al. Endoscopic mucosal resection for flat neoplasia in chronic ulcerative colitis: can we change the endoscopic management paradigm? Gut. 2007;56:838. doi: 10.1136/GUT.2006.106294
30. Annese V, Daperno M, Rutter MD, Amiot A, et al. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis. 2013;7:982–1018. doi: 10.1016/J.CROHNS.2013.09.016
31. Laine L, Kaltenbach T, Barkun A, McQuaid KR, et al. SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. Gastroenterology. 2015;148:639–651.e28. doi: 10.1053/J.GASTRO.2015.01.031
32. Moss A, Bourke MJ, Williams SJ, Hourigan LF, et al. Endoscopic mucosal resection outcomes and prediction of submucosal cancer from advanced colonic mucosal neoplasia. Gastroenterology. 2011;140:1909–18. doi: 10.1053/J.GASTRO.2011.02.062
33. Dignass A, Eliakim R, Magro F, Maaser C, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis. 2012;6:965–90. doi: 10.1016/J.CROHNS.2012.09.003
34. Farraye FA, Odze RD, Eaden J, SH I, et al. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010;138:738–45. doi: 10.1053/J.GASTRO.2009.12.037
35. Feakins RM. Inflammatory bowel disease biopsies: updated British Society of Gastroenterology reporting guidelines. J Clin Pathol. 2013;66:1005–26. doi: 10.1136/JCLINPATH-2013-201885
36. Ullman TA, Croog V, Harpaz N, Sachar D, et al. Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. Gastroenterology. 2003;125:1311–9. doi: 10.1016/J.GASTRO.2003.08.023
37. O’Connell JB, Maggard MA, Livingston EH, Yo CK. Colorectal cancer in the young. Am J Surg. 2004;187:343–8. doi: 10.1016/J.AMJSURG.2003.12.020
38. Carbonnel F, Gargouri D, Lémann M, Beaugerie L, et al. Predictive factors of outcome of intensive intravenous treatment for attacks of ulcerative colitis. Aliment Pharmacol Ther. 2000;14:273–9. doi: 10.1046/J.1365-2036.2000.00705.X
39. Pellino G, Keller DS, Sampietro GM, Carvello M, et al. Inflammatory bowel disease position statement of the Italian Society of Colorectal Surgery (SICCR): ulcerative colitis. Tech Coloproctol. 2020;24:397– 419. doi: 10.1007/S10151-020-02175-Z
40. Pellino G, Keller DS, Sampietro GM, Annese V, et al. Inflammatory bowel disease (IBD) position statement of the Italian Society of Colorectal Surgery (SICCR): general principles of IBD management. Tech Coloproctol. 2020;24:105–26. doi: 10.1007/S10151-019-02145-0
41. Frontali A, Cohen L, Bridoux V, Myrelid P, et al. Segmental Colectomy for Ulcerative Colitis: Is There a Place in Selected Patients Without Active Colitis? An International Multicentric Retrospective Study in 72 Patients. J Crohns Colitis. 2020;14:1687– 92. doi: 10.1093/ECCO-JCC/JJAA107
42. Khan N, Cole E, Shah Y, Paulson EC. Segmental resection is a safe oncological alternative to total proctocolectomy in elderly patients with ulcerative colitis and malignancy. Colorectal Dis. 2017;19:1108–16. doi: 10.1111/CODI.13721
43. Connelly TM, Koltun WA. The surgical treatment of inflammatory bowel disease-associated dysplasia. Expert Rev Gastroenterol Hepatol. 2013;7:307–22. doi: 10.1586/EGH.13.17
44. Caini S, Bagnoli S, Palli D, Saieva C, et al. Total and cancer mortality in a cohort of ulcerative colitis and Crohn’s disease patients: The Florence inflammatory bowel disease study, 1978-2010. Dig Liver Dis. 2016;48:1162–7. doi: 10.1016/J.DLD.2016.07.008
45. Glynne-Jones R, Wyrwicz L, Tiret E, Brown G, et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol. 2017;28:iv22–40. doi: 10.1093/ANNONC/MDX224
46. Sica GS, Biancone L. Surgery for inflammatory bowel disease in the era of laparoscopy. World J Gastroenterol. 2013;19:2445. doi: 10.3748/WJG.V19.I16.2445
47. Remzi FH, Preen M. Rectal cancer and ulcerative colitis: does it change the therapeutic approach? Colorectal Dis. 2003;5:483–5. doi: 10.1046/J.1463-1318.2003.00505.X
48. Merchea A, Wolff BG, Dozois EJ, Abdelsattar ZM, et al. Clinical features and oncologic outcomes in patients with rectal cancer and ulcerative colitis: a single-institution experience. Dis Colon Rectum. 2012;55:881–5. doi: 10.1097/DCR.0B013E31825BF779
49. Monson JRT, Weiser MR, Buie WD, et al. Practice parameters for the management of rectal cancer (revised). Dis Colon Rectum. 2013;56:535–50. doi: 10.1097/DCR.0B013E31828CB66C
50. Song DY, Lawrie WT, Abrams RA, Kafonek DR, et al. Acute and late radiotherapy toxicity in patients with inflammatory bowel disease. Int J Radiat Oncol Biol Phys. 2001;51:455–9. doi: 10.1016/S0360-3016(01)01629-7
51. Spinelli A, Carvello M, Kotze PG, Maroli A, et al. Ileal pouch-anal anastomosis with fluorescence angiography: a case-matched study. Colorectal Dis. 2019;21:827–32. doi: 10.1111/CODI.14611
52. Zmora O, Spector D, Dotan I, Klausner JM, et al. Is stapled ileal pouch anal anastomosis a safe option in ulcerative colitis patients with dysplasia or cancer? Int J Colorectal Dis. 2009;24:1181–6. doi: 10.1007/S00384-009-0744-9
53. Inoue Y, Araki T, Okugawa Y, KawamotoA, et al. Chemoradiotherapy followed by restorative proctocolectomy with partial intersphincteric resection for advanced rectal cancer associated with ulcerative colitis: report of a case. Surg Today. 2014;44:387–90. doi: 10.1007/S00595-013-0558-9
54. Williams NS, Dixon MF, Johnston D. Reappraisal of the 5 centimetre rule of distal excision for carcinoma of the rectum: a study of distal intramural spread and of patients’ survival. Br J Surg. 1983;70:150–4. doi: 10.1002/BJS.1800700305
55. Guillem JG, Chessin DB, Shia J, Suriawinata A, et al. A Prospective Pathologic Analysis Using Whole-Mount Sections of Rectal Cancer Following Preoperative Combined Modality Therapy: Implications for Sphincter Preservation. Ann Surg. 2007;245:88. doi: 10.1097/01.SLA.0000232540.82364.43
56. Hotta S, Shimada Y, Nakano M, Yamada S, et al. Feasibility of restorative proctocolectomy in patients with ulcerative colitisassociated lower rectal cancer: A retrospective study. Asian J Surg. 2019;42:267–73. doi: 10.1016/J.ASJSUR.2018.01.003
57. Fazio VW, Kiran RP, Remzi FH, Coffey JC, et al. Ileal pouch anal anastomosis: analysis of outcome and quality of life in 3707 patients. Ann Surg. 2013;257:679–85. doi: 10.1097/SLA.0b013e31827d99a2
58. Rouanet P, Rivoire M, Gourgou S, Lelong B, et al. Sphinctersaving surgery for ultra-low rectal carcinoma initially indicated for abdominoperineal resection: Is it safe on a long-term follow-up? J Surg Oncol. 2021;123:299–310. doi: 10.1002/JSO.26249
59. Park JS, Park SY, Kim HJ, Cho SH, et al. Long-term Oncologic Outcomes After Neoadjuvant Chemoradiation Followed by Intersphincteric Resection With Coloanal Anastomosis for Locally Advanced Low Rectal Cancer. Dis Colon Rectum. 2019;62:408–16. doi: 10.1097/DCR.0000000000001321
60. Lorenzi B, Brading AF, Martellucci J, Cetta F, et al. Short-term effects of neoadjuvant chemoradiotherapy on internal anal sphincter function: a human in vitro study. Dis Colon Rectum. 2012;55:465–72. doi: 10.1097/DCR.0B013E31824154A0
61. Ito M, Saito N, Sugito M, Kobayashi A, et al. Analysis of clinical factors associated with anal function after intersphincteric resection for very low rectal cancer. Dis Colon Rectum. 2009;52:64–70. doi: 10.1007/DCR.0B013E31819739A0
62. Reynolds IS, O’Toole A, Deasy J, McNamara DA, et al. A meta-analysis of the clinicopathological characteristics and survival outcomes of inflammatory bowel disease associated colorectal cancer. Int J Colorectal Dis. 2017;32:443–51. doi: 10.1007/S00384-017-2754-3
63. Thicoïpé A, Laharie D, Smith D, Chabrun E, et al. Oncological outcomes of IBD-associated versus sporadic colorectal cancer in modern era: a matched case-control study. Int J Colorectal Dis. 2018;33:963–6. doi: 10.1007/S00384-018-3049-Z
Рецензия
Для цитирования:
Расулов А.О., Куликов А.Э., Мадьяров Ж.М., Расулов З.Р. Колоректальный рак на фоне язвенного колита (обзор литературы). Колопроктология. 2023;22(1):138-146. https://doi.org/10.33878/2073-7556-2023-22-1-138-146
For citation:
Rasulov A.O., Kulikov A.E., Madyarov J.M., Rasulov Z.R. Colorectal cancer in ulcerative colitis (review). Koloproktologia. 2023;22(1):138-146. https://doi.org/10.33878/2073-7556-2023-22-1-138-146
Просмотров:
917
Послать статью по эл. почте 
